QuidelOrtho grants equity awards to Chief Legal Officer

SISITSKY NATHANIEL reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

SISITSKY NATHANIEL reported acquisition or exercise transactions in this Form 4 filing.

QuidelOrtho Corp granted its Chief Legal Officer, Nathaniel Sisitksy, new equity awards reported as compensation. He received 73,434 non-qualified stock options exercisable at $17.49 per share, expiring on April 15, 2036, covering 73,434 shares of common stock. He was also granted 73,435 restricted stock units, each representing one share of common stock. For these awards, 24,478 shares are scheduled to vest in equal installments on April 15, 2027 and April 15, 2028, with 24,479 shares vesting on April 15, 2029, and another schedule provides 24,478 shares vesting in equal installments on April 15, 2027, April 15, 2028 and April 15, 2029.

Insider Trade Summary

Grant/Award: 146,869 shares

Grant/Award 2 txns

Insider SISITSKY NATHANIEL

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	73,435	$0.00	$0.00
Grant/Award	Non-Qualified Stock Options	73,434	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 73,435 contracts (Direct); Non-Qualified Stock Options — 73,434 contracts (Direct)

Footnotes (3)

1. F1. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
2. F2. 24,478 shares will vest in equal installments on April 15, 2027 and April 15, 2028; the remaining 24,479 shares will vest on April 15, 2029.
3. F3. 24,478 shares will vest in equal installments on April 15, 2027, April 15, 2028 and April 15, 2029.

Key Figures

Stock options granted: 73,434 options Option exercise price: $17.49 per share Option expiration: April 15, 2036 +3 more

6 metrics

Stock options granted 73,434 options Non-qualified stock options granted on April 15, 2026

Option exercise price $17.49 per share Exercise price for 73,434 non-qualified stock options

Option expiration April 15, 2036 Expiration date of granted non-qualified stock options

RSUs granted 73,435 RSUs Restricted stock units representing common shares

RSU vesting 2027–2029 24,478 / 24,478 / 24,479 shares Scheduled RSU vesting amounts through April 15, 2029

Options vesting 2027–2029 24,478 shares annually One schedule provides 24,478 shares vesting each year 2027–2029

Key Terms

Non-Qualified Stock Options, Restricted Stock Units, vesting, Chief Legal Officer

4 terms

Non-Qualified Stock Options financial

"73,434 non-qualified stock options exercisable at $17.49 per share"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

Restricted Stock Units financial

"He was also granted 73,435 restricted stock units, each representing one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting financial

"24,478 shares will vest in equal installments on April 15, 2027 and April 15, 2028"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Chief Legal Officer financial

"granted its Chief Legal Officer, Nathaniel Sisitksy, new equity awards"

A chief legal officer is a senior executive responsible for overseeing a company's legal matters, ensuring that its activities comply with laws and regulations. They act like a company's legal guide, helping to prevent legal problems and manage risks. For investors, understanding this role is important because it reflects how well a company manages legal risks that could impact its stability and reputation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did QuidelOrtho (QDEL) grant to its Chief Legal Officer?

QuidelOrtho granted its Chief Legal Officer 73,434 non-qualified stock options and 73,435 restricted stock units (RSUs). Both awards are tied to the company’s common stock and represent part of his overall equity-based compensation package.

What is the exercise price and expiration for the new QuidelOrtho (QDEL) stock options?

The new stock options have an exercise price of $17.49 per share and expire on April 15, 2036. These options cover 73,434 shares of QuidelOrtho common stock, giving long-dated potential equity participation.

How many restricted stock units did the QuidelOrtho (QDEL) Chief Legal Officer receive?

He received 73,435 restricted stock units, each representing one share of QuidelOrtho common stock. These RSUs will convert into shares as they vest over several years under the specified vesting schedules.

How do the QuidelOrtho (QDEL) RSU awards vest for the Chief Legal Officer?

One schedule states 24,478 shares vest in equal installments on April 15, 2027 and April 15, 2028, with 24,479 shares vesting on April 15, 2029. Another schedule provides 24,478 shares vesting annually from 2027 through 2029.

Are these QuidelOrtho (QDEL) transactions open-market buys or sells?

No. Both entries are coded as “A” grant or award acquisitions, indicating equity compensation grants, not open-market purchases or sales. The transactions show new options and RSUs awarded, rather than trading activity in the market.

What position does the reporting person hold at QuidelOrtho (QDEL)?

The reporting person, Nathaniel Sisitksy, serves as Chief Legal Officer of QuidelOrtho Corp. The Form 4 reflects equity compensation awards linked to his executive role within the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/22/2026 - 06:14 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SISITSKY NATHANIEL

(Last) (First) (Middle)

9975 SUMMERS RIDGE ROAD

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
QuidelOrtho Corp [ QDEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	04/15/2026		A		73,435		(2)	(2)	Common Stock	73,435	$0	73,435	D
Non-Qualified Stock Options	$17.49	04/15/2026		A		73,434		(3)	04/15/2036	Common Stock	73,434	$0	73,434	D

Explanation of Responses:

1. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.

2. 24,478 shares will vest in equal installments on April 15, 2027 and April 15, 2028; the remaining 24,479 shares will vest on April 15, 2029.

3. 24,478 shares will vest in equal installments on April 15, 2027, April 15, 2028 and April 15, 2029.

Remarks:

	/s/ Jennifer Ahn, attorney-in-fact for Nathaniel Sisitsky	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)